Table 3.
Comparison of ixabepilone/bevacizumab (BEV) with chemotherapy/(BEV) in the AURELIA trial.
| AURELIA | Present study | |
|---|---|---|
| Percent platinum-refractory | 0% | 18% |
| Pre-treatment status |
(i.e. >3 prior lines) 0% (chemotherapy) 0% (chemotherapy + BEV) |
(i.e. >3 prior lines) 51% (IXA) 46% (IXA + BEV) |
| Prior anti-angiogenic therapy |
8% (chemotherapy) 7% (chemotherapy and BEV) |
57% (IXA) 54% (IXA + BEV) |
| Response rate (RECIST) |
12% (chemotherapy) 27% (chemotherapy + BEV) |
8% (IXA) 33% (IXA + BEV) |
| weekly paclitaxela |
30.2% 53.3% (+BEV) |
N/A |
| topotecan* |
0% 17% (+BEV) |
N/A |
| pegylated liposomal doxorubicina |
7.8% 13.7% (+BEV) |
N/A |
| PFS (months) | ||
| Chemotherapy |
3.4 (95% CI 2.2–3.7) |
N/A |
| Chemotherapy + BEV |
6.7 (95CI 5.7–7.9) |
N/A |
| IXA | N/A |
2.2 (95% CI 1.8–3.8) |
| IXA + BEV | N/A |
5.5 (95% CI 4.6–10.0) |
| Weekly Paclitaxela |
3.9 (95% CI 3.5–5.6) |
N/A |
| Weekly Paclitaxel + BEVa |
10.4 (95% CI 7.9–11.9) |
N/A |
| IXA + BEV (BEV-naive) | N/A |
9.9 (95% CI 5.5–17.5) |
| IXA + BEV (prior BEV) | N/A |
4.6 (95% CI 4.0–6.9) |
| OS (months) | ||
| Chemotherapy |
13.3 (95% CI 11.9–16.4) |
N/A |
| Chemotherapy + BEV |
16.6 (95% CI13.7–19.0) |
N/A |
| IXA | N/A |
6.0 (95% CI 4.1–12.1) |
| IXA + BEV | N/A |
10.0 (95% CI 9.1–20.2) |
| Weekly Paclitaxela |
13.2 (95% CI 8.2–19.7) |
N/A |
| Weekly Paclitaxel + BEVa |
22.4 (95% CI 16.7–26.7) |
N/A |
| IXA + BEV (BEV-naive) | N/A |
18.6 (95% CI 9.8–25.4) |
| IXA + BEV (prior BEV) | N/A |
9.4 (95% CI 6.4–16.7) |
| Bowel perforation with BEV | 2% (n = 4) | 2.5% (n = 1) |
CI confidence interval.
aAncillary analyses by Poveda et al. (2015) [45].